HOME > Products and Technologies > Publications
List of Publications on VM202
Expression vector pCK and therapeutic gene HGF
1. Lee et al., Improved expression of vascular endothelial growth factor by naked DNA in mouse skeletal muscles: implication for gene therapy of ischemic diseases. Biochemical and Biophysical Research Communications, 2000;272:230-235.
2. Pyun et al., Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia. Gene Therapy, 2010;17:1442-1452.
Preclinical
3. Carlsson et al., Quantitative MR measurements of regional and global left ventricular function and strain after intramyocardial transfer of VM202 into infarcted swine myocardium. American Journal of Physiology - Heart and Circulatory Physiology, 2008;295(2):H522-H532.
4. Cho et al., Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. European Journal of Cardio-thoracic Surgery, 2008;34:857-863.
5. Saeed et al., MR assessment of myocardial perfusion, viability, and function after intramyocardial transfer of VM202, a new plasmid human hepatocyte growth factor in ischemic swine myocardium. Radiology, 2008;249:107-118.
6. Saeed et al., Cardiovascular magnetic resonance imaging in delivering and evaluating the efficacy of hepatocyte growth factor gene in chronic infarct scar. Cardiovascular Revascularization Medicine, 2011;12:111-122.
7. Perin et al., Human hepatocyte growth factor (VM202) gene therapy via transendocardial injection in a pig model of chronic myocardial ischemia. Journal of Cardiac Failure, 2011;17:601-611.
8. Hahn et al., Enhanced cardio-protective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model. The Journal of Gene Medicine, 2011;13:549-555.
9. Nho et al., Effective control of neuropathic pain by transient expression of hepatocyte growth factor in a mouse chronic constriction injury model. The FASEB Journal, 2018 Apr 16, doi: 10.1096/fj.201800476R [Epub ahead of print]
10. Ko et al., Hepatocyte growth factor (HGF) promotes peripheral nerve regeneration by activating repair Schwann cells. Scientific Reports, 2018 May 29, doi: 10.1038/s41598-018-26704-x [Epub ahead of print]
11. Choi et al., Hepatocyte Growth Factor Regulates the miR-206-HDAC4 Cascade to Control Neurogenic Muscle Atrophy following Surgical Denervation in Mice. Molecular Therapy-Nucleic Acids, 2018; 12;568-577.
Clinical
1.

VM202-PAD (Critical Limb Ischemia)

Henry et al., Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study. Gene Therapy, 2011;18:788-794.
2.

VM202-PAD (Critical Limb Ischemia)

Gu et al., A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia. The Journal of Gene Medicine, 2011;13:602-610.
3.

VM202-CAD (Ischemic Heart Disease)

Kim et al., Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study. Gene Therapy, 2013;20:717-722.
4.

VM202-DPN (Diabetic Peripheral Neuropathy)

Ajroud‐Driss et al., Phase 1/2 open-label dose-escalation study of plasmid DNA expressing hepatocyte growth factor in patients with painful diabetic neuropathy. Molecular Therapy, 2013;21:1279-1286.
5.

VM202-DPN (Diabetic Peripheral Neuropathy)

Kessler et al., Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy. Annals of Clinical and Translational Neurology, 2015;2:465-478.
6.

VM202-PAD (Critical Limb Ischemia)

Kibbe et al., Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia. Gene Therapy, 2016;3:306-312.
7.

VM202-ALS (Amyotrophic Lateral Sclerosis)

Robert L. Sufit et al., Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017 May;18(3-4):269-278.
List of Publications on VM206RY
1. Kim et al., Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen. International Journal of Cancer, 2002;102:428–434.
2. Lee et al., Comparison of the antitumor efficacies of Her-2/neu DNA vaccines inducing contrasting IgG immunity but comparable CTL activity in mice. Vaccine, 2003;21:521–531.
3. Chang et al., Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. International Journal of Cancer, 2004;111:86-95.
4. Ko et al., Immunogenicity and safety profiles of genetic vaccines against human Her-2/neu in cynomolgus monkeys. Gene Therapy, 2008;15:1351-1360.
List of Publications on VM501
Preclinical
1. Jung et al., Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis. Biochemical and Biophysical Research Communications, 2011;405:399-404.
Clinical
1. Wu et al., Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy. Support Care Cancer, 2012;20:1875-1884.
List of Publications on PG102
Preclinical
1. Park et al., Control of IgE and selective T(H)1 and T(H)2 cytokines by PG102 isolated from Actinidia argute. Journal of Allergy and Clinical Immunology, 2005;116:1151-1157.
2. Chen et al., Evaluation of IgE binding to proteins of hardy (Actinidia arguta), gold (Actinidia chinensis) and green (Actinidia deliciosa) kiwifruits and processed hardy kiwifruit concentrate, using sera of individuals with food allergies to green kiwifruit. Food and Chemical Toxicology, 2006;44:1100–1107.
3. Park et al., Suppression of spontaneous dermatitis in NC/Nga murine model by PG102 isolated from Actinidia arguta. Journal of Investigative Dermatology, 2007;127:1154-1160.
4. Hong et al., Subacute toxicological study of PG102, a water-soluble extract derived from Actinidia arguta, in SD rats. Korean Journal of Veterinary Research, 2008;48:413-421.
5. Choi et al., Blockade of atopic dermatitis-like skin Lesions by DA-9102, a natural medicine Isolated from Actinidia arguta, in the Mg-deficiency induced dermatitis model of hairless rats. Experimental Biology and Medicine, 2008;233:1026-1034.
6. Kim et al., Anti-allergic effects PG102, a water-soluble extract prepared from Actinidia arguta, in a murine OVA-induced asthma model. Clinical and Experimental Allergy, 2009;39:280-289.
7. 7. Kim et al., Suppression of allergic diarrhea in murine OVA-induced food allergy model by PG102, a water-soluble extract prepared from Actinidia arguta. International Archives of Allergy and Immunology, 2009;150:164-171.
8. 8. Ho et al., Effect of PG102, a water-soluble extract from Actinidia arguta on canine atopic dermatitis. Korean Journal of Pharmacognosy, 2009;40: 59-64.
Clinical
1. Marsella et al., A randomized, double-blind, placebo-controlled study to evaluate the effect of EFF1001 (PG102), an Actinidia arguta (hardy kiwi) preparation, on CADESI score and pruritus in dogs with mild to moderate atopic dermatitis. Veterinary Dermatology, 2010;21:50-57.
2. Kim et al., The effects of PG102, a water soluble extract from Actinidia arguta, 1 on serum total IgE 2 levels; A double blind, randomized, placebo-controlled exploratory clinical study. European Journal of Nutrition, 2011;50:523-529.
3. Kim et al., Reconstitution of anti-allergic activities of PG102 derived from Actinidia arguta by combining synthetic chemicalcompounds. Experimental Biology and Medicine, 2013;238(6):631-640.
List of Publications on PG201
Preclinical
1. Shin et al., Suppressive effects of PG201, an ethanol extract from herbs, on collagen induced arthritis in mice. Rheumatology, 2003;42:665-672.
2. Park et al., Therapeutic effects of PG201, an ethanol extract from herbs, through cartilage protection on collagenase-induced arthritis in rabbits. Biochemical and Biophysical Research Communications, 2005;331:1469-1477.
3. Choi et al., Suppressive effects of PG201, an antiarthritic botanical formulation, on lipopolysaccharide-induced inflammatory mediators in Raw264.7 cells. Experimental Biology and Medicine, 2012;237:499-508.
4. Choi et al., PG201 downregulates the production of nitrite by upregulating heme oxygenase-1 expression through the control of phosphatidylinositol 3-kinase and NF-E2-related factor 2. Nitric Oxide, 2013;33C:42-55.
5. Bae et al., PG201 protects mice from experimental autoimmune encephalomyelitis via suppression of effector T cell activation. Phytomedicine, 2018 April;1(43):150-157.
Clinical
1. Kang, et al., A double-blind, randomized, placebo-controlled exploratory clinical study to assess the efficacy, dose responses, and safety of PG201 in patients with osteoarthritis of the knee. 2012, Submitted for publication (Phase II study in Korea)
2. Yoo et al., Efficacy and safety of PG201 and celecoxib in the treatment of symptomatic knee osteoarthritis; A double blinded, randomized, multi-center, active drug comparative, parallel-group non-inferiority, phase III study. Rheumatology International, 2014;34:1369-1387
List of Publications on HX106
Preclinical
1. Lee, et al., Ameliorating effects of HX106N, a water-soluble botanical formulation, on Aβ25-35-induced memory impairment and oxidative stress in mice. Biological and Pharmaceutical Bulletin, 2014;37(6): 954-960
2. Lee, et al., Effects of HX106N, a water-soluble botanical formulation on scopolamine-induced memory impairment in mice. Korean Journal of Food and Nutrition, 2014;27:673-677
3. Lee, et al., Effective suppression of nitric oxide production by HX106N through transcriptional control of heme oxygenase-1. Experimental Biology and Medicine, 2015;240(9):1136-1146
Clinical
1. Kwon, et al., Effects of the combination herbal extract on working memory and white matter integrity in healthy Individuals with subjective memory complaints: A randomized, double-blind, placebo-controlled clinical trial. Korean Journal of Biological Psychiatry, 2015;22(2):63-77.
List of Publications on DHCA
Preclinical
1. Choi, et al., A water-soluble extract from Cucurbita moschata shows anti-obesity effects by controlling lipid metabolism in a high fat diet-induced obesity mouse model. Biochemical and Biophysical Research Communications, 2007;359(3):419-425.
2. Lee, et al., Dehydrodiconiferyl alcohol isolated from Cucurbita moschata shows anti-adipogenic and anti-lipogenic effect in 3T3-L1 cells. Journal of Biological Chemistry, 2012;287(12):8839-8851.
3. Lee, et al., Upregulation of heme oxygenase-1 expression by dehydrodiconiferyl alcohol (DHCA) through the AMPK-Nrf2 dependent pathway. Toxicology and Applied Pharmacology, 2014;281(1): 87–100.
4. Lee, et al., Effective suppression of pro-inflammatory molecules by DHCA via IKK-NF-κB pathway, in vitro and in vivo. British Journal of Pharmacology, 2015;172(13):3353-3369.
5. Lee, et al., Dehydrodiconiferyl alcohol (DHCA) modulates the differentiation of Th17 and Th1 cells and suppresses experimental autoimmune encephalomyelitis. Molecular Immunology, 2015;68(2):434-444.